New hope for hard-to-treat ovarian cancer: combo therapy enters human trial
NCT ID NCT07495384
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called CapsuleX combined with cisplatin in 40 people whose ovarian cancer no longer responds to platinum-based chemotherapy. The goal is to see if the combination can shrink tumors and how safe it is. Participants must have confirmed ovarian, fallopian tube, or primary peritoneal cancer that is platinum-resistant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Hospital of Jilin University
RECRUITINGChangchun, Jilin, 130000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a custom vaccine train the body to fight ovarian cancer?
- Can a 'Smart Bomb' drug outsmart recurrent ovarian cancer?
- Can a Two-Drug combo outsmart resistant ovarian cancer?
- Can a targeted drug boost standard ovarian cancer therapy?
- Can heated chemo during surgery help older women with ovarian cancer?
- Can a daily pill keep BRCA-Linked ovarian cancer at bay?